Literature DB >> 17535043

Conventional and atypical antipsychotics in the elderly : a review.

Pietro Gareri1, Pasquale De Fazio, Mariagrazia Stilo, Guido Ferreri, Giovambattista De Sarro.   

Abstract

Psychoses are major mental disorders marked by derangement of personality and loss of contact with reality, and are common in the elderly. Various hypotheses suggest the pivotal role of abnormal neurotransmitter and neuropeptide systems in psychotic patients, the most studied of which are the dopaminergic, serotonergic and glutamatergic systems. In particular, long-term treatment with antagonists at dopamine (D) and serotonin (5-hydroxytryptamine; 5-HT) receptors and agonists at glutamate receptors may improve symptoms. Treatment with antipsychotics is very common in the elderly and often indispensable. However, for successful treatment it is essential to have an adequate multidimensional assessment of the geriatric patient and of his or her polypathology and polypharmacy, together with knowledge of age-dependent pharmacokinetics and pharmacodynamic changes and drug-drug interactions.Conventional antipsychotics such as haloperidol, chlorpromazine, promazine, tiapride and zuclopenthixol are D(2)-receptor antagonists and inhibit dopaminergic neurotransmission in a dose-related manner. They decrease the intensity of all psychotic symptoms, although not necessarily to the same extent and with the same time course. Negative symptoms may persist to a much more striking extent than delusions, hallucinations and thought disorders, and there is a dose-related incidence of extrapyramidal side effects (EPS). Newer antipsychotics, such as clozapine, olanzapine, risperidone, quetiapine and ziprasidone, have a different receptor-binding profile, interacting with both D and 5-HT receptors; they less frequently cause EPS and are better tolerated in the elderly. Their use is advantageous because they are effective both on positive and negative symptoms of schizophrenia and may also be used in the treatment of behavioural disturbances in elderly and/or demented individuals. The use of clozapine is limited by the onset of agranulocytosis, whereas olanzapine, risperidone, quetiapine and, more recently, ziprasidone are widely used, with good results in the above-mentioned diseases.

Entities:  

Year:  2003        PMID: 17535043     DOI: 10.2165/00044011-200323050-00001

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  184 in total

1.  The new antipsychotic compounds: is a clinical choice algorithm possible?

Authors:  W C Wirshing
Journal:  West J Med       Date:  1998-07

2.  Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients.

Authors:  M Toru; S Watanabe; H Shibuya; T Nishikawa; K Noda; H Mitsushio; H Ichikawa; A Kurumaji; M Takashima; N Mataga
Journal:  Acta Psychiatr Scand       Date:  1988-08       Impact factor: 6.392

3.  Olanzapine use in the elderly: a retrospective analysis.

Authors:  K Solomons; O Geiger
Journal:  Can J Psychiatry       Date:  2000-03       Impact factor: 4.356

4.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

5.  The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia.

Authors:  M Brecher; I W Rak; K Melvin; A M Jones
Journal:  Int J Psychiatry Clin Pract       Date:  2000       Impact factor: 1.812

6.  Risperidone in the treatment of elderly patients with psychotic disorders.

Authors:  S Madhusoodanan; M Brecher; R Brenner; J Kasckow; M Kunik; A E Negrón; N Pomara
Journal:  Am J Geriatr Psychiatry       Date:  1999       Impact factor: 4.105

7.  Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2'-iodospiperone.

Authors:  J E Leysen; W Gommeren; J Mertens; W H Luyten; P J Pauwels; M Ewert; P Seeburg
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.

Authors:  G Movin-Osswald; J Boelaert; M Hammarlund-Udenaes; L B Nilsson
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 9.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

10.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

Authors:  P A Janssen; C J Niemegeers; F Awouters; K H Schellekens; A A Megens; T F Meert
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

View more
  7 in total

1.  Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.

Authors:  Rita Citraro; Antonio Leo; Rossana Aiello; Michela Pugliese; Emilio Russo; Giovambattista De Sarro
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 2.  Adverse effects of atypical antipsychotics in the elderly: a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Salvatore De Fazio; Norma Marigliano; Guido Ferreri Ibbadu; Giovambattista De Sarro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Use of atypical antipsychotics in the elderly: a clinical review.

Authors:  Pietro Gareri; Cristina Segura-García; Valeria Graziella Laura Manfredi; Antonella Bruni; Paola Ciambrone; Gregorio Cerminara; Giovambattista De Sarro; Pasquale De Fazio
Journal:  Clin Interv Aging       Date:  2014-08-16       Impact factor: 4.458

Review 4.  Antipsychotic inductors of brain hypothermia and torpor-like states: perspectives of application.

Authors:  Yury S Tarahovsky; Irina S Fadeeva; Natalia P Komelina; Maxim O Khrenov; Nadezhda M Zakharova
Journal:  Psychopharmacology (Berl)       Date:  2016-12-08       Impact factor: 4.530

5.  The geriatric population and psychiatric medication.

Authors:  Sannidhya Varma; Himanshu Sareen; J K Trivedi
Journal:  Mens Sana Monogr       Date:  2010-01

6.  Use of Central Nervous System (CNS) Medicines in Aged Care Homes: A Systematic Review and Meta-Analysis.

Authors:  Syed Shahzad Hasan; Syed Tabish Razi Zaidi; Jorabar Singh Nirwan; Muhammad Usman Ghori; Farideh Javid; Keivan Ahmadi; Zaheer-Ud-Din Babar
Journal:  J Clin Med       Date:  2019-08-23       Impact factor: 4.241

7.  Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units.

Authors:  Maria Gustafsson; Stig Karlsson; Hugo Lövheim
Journal:  BMC Pharmacol Toxicol       Date:  2013-02-08       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.